This website works best with Internet Explorer. If you are not using Internet Explorer and are unable to view the statement, please click here: Statement

EASD Statement:

Lantus insulin: a possible link with cancer which requires further investigation


Diabetologia, the journal of the EASD, currently has a series of four papers and an Editorial

in print, all relating to a possible link between insulin glargine (Lantus insulin) and cancer.

EASD
advises that patients do not stop taking insulin glargine based upon the information presented on this website. If you wish to have further information you should contact your

doctor. 

Advance copies of
the papers and relevant patient information can be downloaded by

following the links below. 

These studies are described and commented on in greater detail in the attached webcast by Professor Ulf Smith (University of Göteborg, Sweden), and Professor Edwin Gale (University

of Bristol, UK).

EASD emphasises that the studies reported are far from conclusive, but they do indicate the need for further investigation of this issue.

The transcript of the statement by Prof
essor Smith and Professor Gale is available here: Transcript

Papers:


 

Editorial
Does diabetes therapy influence the risk of cancer?

U. Smith, E. A. M. Gale
Download

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

L. G. Hemkens, U. Grouven, R. Bender, C. Günster, S. Gutschmidt, G. W. Selke, P. T. Sawicki
Download

Insulin glargine use and short-term incidence of malignancies–a population-based follow-up study in Sweden

J. M. Jonasson, R. Ljung, M. Talbäck, B. Haglund, S. Gudbjörnsdòttir, G. Steineck
Download

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

C. J. Currie, C. D. Poole, E. A. M. Gale
Download

Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group

SDRN Epidemiology Group
Download

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study

J. Rosenstock, V. Fonseca, J. B. McGill, M. Riddle, J.-P. Hallé, I. Hramiak, P. Johnston, M. Davis
Download

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

J. Rosenstock, V. Fonseca, J. B. McGill, M. Riddle, J.-P. Hallé, I. Hramiak, P. Johnston, M. Davis
Download


Patient information from the EASD

Patient information from Hemkens et al.

Further information from the SDRN Epidemiology Group

European Medicines Agency update on safety of insulin glargine